News
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1
Jaguar Health, Inc. receives $16M non-dilutive capital from U.S. license agreement with Future Pak for crofelemer drugs. Strategy focuses on rare-disease intestinal failure indications -
-